ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,765
0,16%
Bitcoin
58 922,45
-0,34%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Galectin Therapeutics Inc (GALT)

  7. Galectin Therapeutics Inc (GALT) Actualités

GALT Galectin Therapeutics Inc

3,37
-0,13 (-3,71%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Galectin Therapeutics Inc GALT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,13 -3,71% 3,37 01:46:14
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,51 3,23 3,54 3,37 3,50
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
04/3/202418:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202417:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202414:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202314:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:15EDGAR2Form 8-K - Current report
07/12/202317:42EDGAR2Form 8-K - Current report
01/12/202322:50EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
01/12/202322:38EDGAR2Form SC 13D/A - General statement of acquisition of..
01/12/202314:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202323:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202315:21EDGAR2Form 8-K/A - Current report: [Amend]
13/11/202314:45GLOBEUPDATE – Galectin Therapeutics Reports Financial Results for..
13/11/202314:00GLOBEGalectin Therapeutics Reports Financial Results for the..
13/11/202313:55EDGAR2Form 8-K - Current report
13/11/202313:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202313:00GLOBEGalectin Therapeutics to Share Five Scientific Presentations..
31/10/202321:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/10/202314:00GLOBEGalectin Therapeutics to Participate in the H.C. Wainwright..
16/10/202314:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/10/202314:00GLOBEGalectin Therapeutics Announces Nomination of Dr. Benjamin..
06/10/202314:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/10/202314:03EDGAR2Form DEF 14A - Other definitive proxy statements
03/10/202314:00GLOBEGalectin Therapeutics Reports the Positive Outcome of the..
02/10/202313:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/9/202320:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202314:00GLOBEGalectin Therapeutics to Present Update on its Belapectin..
18/9/202315:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/9/202322:38EDGAR2Form 144 - Report of proposed sale of securities
11/9/202314:00GLOBEGalectin Therapeutics to Participate in the H.C. Wainwright..
07/9/202318:00GLOBEGalectin Therapeutics to Present Data on Liver Cirrhosis at..
01/9/202313:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/8/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202314:00GLOBEGalectin Therapeutics Reports Financial Results for the..
14/8/202313:55EDGAR2Form 8-K - Current report
14/8/202313:51EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/7/202322:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/7/202313:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202314:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202313:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
GALT
Galectin Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés